Thus, circGFRA1 can function as a regulator of miR-361-5p/TLR4 and by blocking TLR4, the responsiveness of TNBC cells to PTX could be significantly enhanced, improving their sensitivity to the drug in BC treatment (Fig. 6) (Table 5) (Misir et al. 2022). Here, TLR4 is linked to breast cancer.